Mastering the Complexity of AML Treatment:
A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management

Faculty

Courtney DiNardo, MD

Professor of Medicine, Department of Leukemia Anderson Cancer Center
Houston, TX

Amir T, Fathi, MD

Director, Leukemia Program, Massachusetts General Hospital
Associate professor of Medicine, Harvard Medical School
Cambridge, MA

Brian A. Jonas, MD, PhD

Professor of Medicine, University of California Davis School of Medicine
Davis, CA

Program Overview

Health care providers who treat acute myeloid leukemia (AML) have seen several agents approved in the United States in recent years, including FLT3 inhibitors, IDH inhibitors, a liposomal formulation of cytarabine/daunorubicin, a BCL-2 inhibitor, an anti-CD33 antibody-drug conjugate, a hedgehog signaling inhibitor, and oral azacytidine in the maintenance setting. While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option.  This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms. 

Target Audience

This educational program is directed toward community-based medical oncologists, hematologic oncologists, hematologists, hematopathologists, BMT specialists, NP/PAs, nurses, and pharmacists, other healthcare professionals involved in the treatment of AML. 

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • DISCUSS the impact of molecular testing, risk stratification, and measurable residual disease (MRD) on treatment selection and personalization in patients with AML.
  • UTILIZE trial evidence and guideline-based recommendations concerning targeted therapies to manage AML case scenarios typically encountered in community settings.
  • DEVELOP effective strategies to monitor for and manage treatment-related toxicities in patients with AML. 

Educational Activities

Social Media Broadcasts
Podcast
Threads
AML Provider Tool Kit

SOCIAL MEDIA BROADCAST ONE

Credit Amount: 0.25
Credit Type: ACCME, ANCC, ACPE
Release: 9/27/2024
Expiration: 9/27/2025

SOCIAL MEDIA BROADCAST TWO

Credit Amount: 0.25
Credit Type: ACCME, ANCC, ACPE
Release: 9/30/2024
Expiration: 9/30/2025

Clinical Resource Center

Credit Amount: Non-certified

PODCAST ONE

Credit Amount: 0.25
Credit Type: ACCME, ANCC, ACPE
Release: 9/27/2024
Expiration: 9/27/2025

PODCAST TWO

Credit Amount: 0.25
Credit Type: ACCME, ANCC, ACPE
Release: 9/30/2024
Expiration: 9/30/2025

THREADS ONE

Credit Amount: 0.25
Credit Type: ACCME, ANCC, ACPE
Release: 9/27/2024
Expiration: 9/27/2025

THREADS TWO

Credit Amount: 0.25
Credit Type: ACCME, ANCC, ACPE
Release: 9/30/2024
Expiration: 9/30/2025

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT
This educational activity is supported by independent educational grants from AbbVie Inc. and Astellas Pharma Global Development, Inc.

Maximum Credit Amount: 1.50
Credit Type: AMA, ANCC, ACPE
Release: September 27, 2024
Expiration: September 30, 2025